Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: A prospective multicentre study

The Lancet

Volumn 383, Issue 9915, 2014, Pages 436-448

  Güngör, Tayfun ^a   Teira, Pierre ^b   Slatter, Mary ^c   Stussi, Georg ^d   Stepensky, Polina ^e   Moshous, Despina ^f   Vermont, Clementien ^g   Ahmad, Imran ^h   Shaw, Peter J ⁱ   Da Cunha, José Marcos Telles ^j   Schlegel, Paul G ^k   Hough, Rachel ^l   Fasth, Anders ^m   Kentouche, Karim ⁿ   Gruhn, Bernd ⁿ   Fernandes, Juliana F ^o   Lachance, Silvy ^h   Bredius, Robbert ^g   Resnick, Igor B ^e   Belohradsky, Bernd H ^p   Gennery, Andrew ^c   Fischer, Alain ^f   Gaspar, H Bobby ^q,r   Schanz, Urs ^d   Seger, Reinhard ^a   Rentsch, Katharina ^d,s   Veys, Paul ^q,r   Haddad, Elie ^b   Albert, Michael H ^p   Hassan, Moustapha ^s,t   Fraser, C J ^u   Wawer, A ^v   Kalwak, K ^w   Duffiner, U ^x   more..

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY OF MONTREAL   (Canada)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

ⁱ SYDNEY CHILDREN'S HOSPITAL   (Australia)

^j HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^k UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^l UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^m UNIVERSITY OF GOTHENBURG   (Sweden)

ⁿ JENA UNIVERSITY HOSPITAL   (Germany)

^o UNIVERSITY OF SÃO PAULO   (Brazil)

^p LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^q GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^r UNIVERSITY COLLEGE LONDON   (United Kingdom)

^s KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^t KAROLINSKA INSTITUTE   (Sweden)

^u ROYAL CHILDREN'S HOSPITAL   (Australia)

^v Klinikum Schwabing   (Germany)

^w WROCLAW MEDICAL UNIVERSITY   (Poland)

^x HELEN DEVOS CHILDREN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOSPORIN A; FLUDARABINE; FLUORODEOXYGLUCOSE F 18; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ADULT DISEASE; AREA UNDER THE CURVE; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BK VIRUS INFECTION; BLOOD GROUP ABO INCOMPATIBILITY; BRONCHIOLITIS OBLITERANS; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; CHIMERA; CHOLECYSTITIS; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC GRANULOMATOUS DISEASE; COLITIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CYSTITIS; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; ENGRAFTMENT; EPSTEIN BARR VIRUS INFECTION; ERYTHROCYTE TRANSFUSION; EVENT FREE SURVIVAL; FEMALE; FOLLICULITIS; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; IATROGENIC DISEASE; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; INCIDENCE; INFLAMMATION; INTERVERTEBRAL DISK DEGENERATION; KARYOTYPING; KIDNEY FAILURE; LIVER ABSCESS; LOW DRUG DOSE; LUNG ASPERGILLOSIS; LUNG GRANULOMA; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELOABLATIVE CONDITIONING; NEPHROTIC SYNDROME; NEUTROPHIL; OVERALL SURVIVAL; PANCREATITIS; PERIANAL ABSCESS; PLASMAPHERESIS; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDALLESCHERIASIS; PURE RED CELL ANEMIA; RADIATION DOSE; RECOMMENDED DRUG DOSE; REDUCED INTENSITY CONDITIONING; REPEAT PROCEDURE; RETRANSPLANTATION; ROTAVIRUS INFECTION; STAPHYLOCOCCUS INFECTION; WHOLE BODY RADIATION; YOUNG ADULT;

EID: 84895068883     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62069-3     Document Type: Article

References (32)

1. van den Berg JM, van Koppen E, Ahlin A, et al. Chronic granulomatous disease: the European experience. PLoS One 2009; 4: e5234.
2. Winkelstein JA, Marino MC, Johnston RB Jr, et al Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79: 155-69.
3. Reichenbach J, Lopatin U, Mahlaoui N., et al Actinomyces in chronic granulomatous disease: an emerging and unanticipated pathogen. Clin Infect Dis 2009; 49: 1703-10.
4. Seger RA. Advances in the diagnosis and treatment of chronic granulomatous disease. Curr Opin Hematol 2011; 18: 36-41.
5. Meissner F, Seger RA, Moshous D, Fischer A., Reichenbach J, Zychlinsky A. Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. Blood 2010; 116: 1570-73.
6. Deffert C., Carnesecchi S, Yuan H., et al Hyperinflammation of chronic granulomatous disease is abolished by NOX2 reconstitution in macrophages and dendritic cells. J Pathol 2012; 228: 341-50.
7. Freudenberg F, Wintergerst U, Roesen-Wolff A, et al Therapeutic strategy in p47-phox deficient chronic granulomatous disease presenting as inflammatory bowel disease. J Allergy Clin Immunol 2010; 125: 943-46.
8. Kuhns DB, Alvord WG, Heller T, et al Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 2010; 363: 2600-10.
9. The Westminster Hospitals Bone-Marrow Transplant Team. Bone-marrow transplant from an unrelated donor for chronic granulomatous disease. Lancet 1977; 309: 210-13.
10. Seger RA, Gungor T, Belohradsky B.H., et al Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood 2002; 100: 4344-50.
11. Schuetz C, Hoenig M, Gatz S., et al Hematopoietic stem cell transplantation from matched unrelated donors in chronic granulomatous disease. Immunol Res 2009; 44: 35-41.
12. Soncini E, Slatter MA, Jones L.B., et al Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol 2009; 145: 73-83.
13. Honig M, Flegel WA, Schwarz K, et al Successful hematopoietic stem-cell transplantation in a patient with chronic granulomatous disease and McLeod phenotype sensitized to Kx and K antigens. Bone Marrow Transplant 2010; 45: 209-11.
14. Martinez CA, Shah S, Shearer W T, et al Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol 2012; 129: 176-83.
15. Tewari P, Martin PL, Mendizabal A, et al Myeloablative transplantation using either cord blood or bone marrow leads to immune recovery, high long-term donor chimerism and excellent survival in chronic granulomatous disease. Biol Blood Marrow Transplant 2012; 18: 1368-77.
16. Horwitz ME, Barrett AJ, Brown M.R., et al Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med 2001; 344: 881-88.
17. Segal BH, Veys P, Malech H., Cowan MJ Chronic granulomatous disease: lessons from a rare disorder. Biol Blood Marrow Transplant 2011; 17 (suppl 1): S123-31.
18. WHO. Handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
19. Vassal G, Michel G, Esperou H., et al Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol 2008; 61: 113-23.
20. Malar R, Sjoo F, Rentsch K., Hassan M, Gungor T. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients. Pediatric Transplantation 2011; 15: 580-88.
21. Bartelink IH, Bredius RG, Ververs T.T., et al Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 88-98.
22. Olavarria E, Hassan M, Eades A., et al A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. Leukemia 2000; 14: 1954-59.
23. Slavin S, Nagler A, Naparstek E., et al Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-63.
24. Jacobsohn DA, Duerst R, Tse W., Kletzel M. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet 2004; 364: 156-62.
25. Gungor T, Halter J, Klink A., et al Successful low toxicity hematopoietic stem cell transplantation for high-risk adult chronic granulomatous disease patients. Transplantation 2005; 79: 1596-606.
26. Rao K, Amrolia PJ, Jones A, et al Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005; 105: 879-85.
27. Hassan M, Ljungman P, Bolme P., et al Busulfan availability. Blood 1994; 84: 2144-50.
28. Hassan Z, Hassan M, Hellstrom-Lindberg E. The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro. Leukemia 2001; 15: 1240-47.
29. Hassan Z, Hellstrom-Lindberg E, Alsadi S., Edgren M, Hagglund H, Hassan M. The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo. Bone Marrow Transplant 2002; 30: 141-47.
30. Chakraverty R, Orti G, Roughton M., et al Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood 2010; 116: 3080-88.
31. Bresters D, van Gils IC, Kollen WJ, et al High burden of late effects after haematopoietic stem cell transplantation in childhood: a single-centre study. Bone Marrow Transplant 2010; 45: 79-85.
32. Gungor T, Albert M, Slatter M., et al Favourable outcome after reduced-toxicity conditioning with high-dose fludarabine, serotherapy and low-dose/targeted busulfan in 74 children and adults with non-malignant diseases. Bone Marrow Transplant 2012; 47: S67-68.